60 patents
Utility
Compositions useful for treating disorders related to KIT
28 Nov 23
Compounds and compositions useful for treating disorders related to mutant KIT are described herein.
Brian L. Hodous, Joseph L. Kim, Kevin J. Wilson, Douglas Wilson, Yulian Zhang
Filed: 9 Nov 22
Utility
CDK2 Inhibitors
12 Oct 23
Douglas Wilson, Neil Bifulco, JR., Natasja Brooijmans, Joseph L. Kim, Emanuele Perola, Philip D. Ramsden, Richard Vargas, Steven Mark Wenglowsky
Filed: 8 Feb 23
Utility
Solid Forms of Pralsetinib
21 Sep 23
The compound cis)-N—((S)-1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethyl)-1-methoxy-4-(4 methyl-6-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-yl)cyclohexanecarboxamide can be prepared as a free base in various crystalline solid forms, and in various salt forms each having one or more solid forms.
Joshua Waetzig, Gordon D. Wilkie, Lauren MacEachern, Kimberly Jean Miller
Filed: 28 May 21
Utility
Crystalline Forms of (S)-1-(4-FLUOROPHENYL)-1-(2-(4-(6-(1-METHYL-1H-PYRAZOL-4-YL)PYRROLO[2,1-F][1,2,4]TRIAZIN-4-YL)PIPERAZINYL)-PYRIMIDIN-5-YL)ETHAN-1-AMINE and Methods of Making
31 Aug 23
Joshua D. Waetzig, Gordon Wilkie
Filed: 8 Dec 22
Utility
EGFR inhibitors
8 Aug 23
Natasja Brooijmans, Jason D. Brubaker, John Emmerson Campbell, Christopher De Savi, Thomas A. Dineen, Meredith Suzanne Eno, Joseph L. Kim, Aysegul Ozen, Emanuele Perola, Brett D. Williams, Douglas Wilson, Kevin J. Wilson
Filed: 8 Aug 22
Utility
Pralsetinib Pharmaceutical Compositions
29 Jun 23
The present disclosure relates to pharmaceutical composition comprising 1) an amorphous solid dispersion comprising pralsetinib, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable hydrophilic polymer; and 2) an effervescent couple; and crystalline forms of pralsetinib and pralsetinib hydrochloride salt, which are useful as a RET selective inhibitors.
Joshua Waetzig, Gordon D. Wilkie, Debra L. Mazaik, Csanad M. Varga, Lia Rogal, Lauren MacEachern, Kimberly Jean Miller, Shellie Rigby-Singleton, Ian A. Barker, Robert J. Harris, Aimee J. Spenceley, Dipak Gordhan
Filed: 28 May 21
Utility
CDK2 Inhibitors
25 May 23
Douglas Wilson, Neil Bifulco, Jr., Natasja Brooijmans, Joseph L. Kim, Emanuele Perola, Philip D. Ramsden, Richard Vargas, Steven Mark Wenglowsky
Filed: 27 Jun 22
Utility
MAP4K1 Inhibitors
11 May 23
One embodiment of the disclosure is a compound represented by Formula I or a pharmaceutically acceptable salt thereof.
Jason D. Brubaker, Michael J. Burke, Joshua T. Close, Thomas A. Dineen, Joseph L. Kim, Chandrasekhar V. Miduturu, Emanuele Perola
Filed: 18 Oct 22
Utility
Compositions Useful for Treating Disorders Related to Kit
27 Apr 23
Compounds and compositions useful for treating disorders related to mutant KIT are described herein.
Brian L. Hodous, Joseph L. Kim, Kevin J. Wilson, Douglas Wilson, Yulian Zhang
Filed: 9 Nov 22
Utility
Inhibitors of activin receptor-like kinase
25 Apr 23
Described herein are compounds that inhibit ALK2 and its mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.
Natasja Brooijmans, Jason D. Brubaker, Paul E. Fleming, Brian Lewis Hodous, Joseph L. Kim, Brett D. Williams, Douglas Wilson, Kevin J. Wilson, Mark Cronin
Filed: 29 May 20
Utility
Crystalline Forms of (S)-1-(4-FLUOROPHENYL)-1-(2-(4-(6-(1-METHYL-1H-PYRAZOL-4-YL)PYRROLO[2,1-F][1,2,4]TRIAZIN-4-YL)PIPERAZINYL)-PYRIMIDIN-5-YL)ETHAN-1-AMINE and Methods of Making
20 Apr 23
Brenton Mar
Filed: 8 Dec 22
Utility
MAP4K1 Inhibitors
13 Apr 23
Jason D. Brubaker, Joshua T. Close, Thomas A. Dineen, Chandrasekhar V. Miduturu, Emanuele Perola
Filed: 13 Jul 22
Utility
Egfr Inhibitors
23 Feb 23
John Emmerson Campbell, Thomas A. Dineen, Natasja Brooijmans, Jason D. Brubaker, Meredith Suzanne Eno, Joseph L. Kim, Aysegül Özen, Emanuele Perola, Brett D. Williams, Douglas Wilson, Kevin J. Wilson, Christopher De Savi
Filed: 29 Oct 21
Utility
Egfr Inhibitors
26 Jan 23
Natasja Brooijmans, Jason D. Brubaker, John Emmerson Campbell, Christopher De Savi, Thomas A. Dineen, Meredith Suzanne Eno, Joseph L. Kim, Aysegul Ozen, Emanuele Perola, Brett D. Williams, Douglas Wilson, Kevin J. Wilson
Filed: 8 Aug 22
Utility
Egfr Inhibitors
19 Jan 23
Omar Ahmad, John Emmerson Campbell, Thomas A. Dineen, Meredith Suzanne Eno, Dilinie Prasadhini Fernando
Filed: 9 Aug 22
Utility
MAP4K1 inhibitors
27 Dec 22
One embodiment of the disclosure is a compound represented by Formula I or a pharmaceutically acceptable salt thereof.
Jason D. Brubaker, Chandrasekhar V. Miduturu, Michael J. Burke, Thomas A. Dineen, Joseph L. Kim, Joshua T. Close, Emanuele Perola
Filed: 14 Jan 21
Utility
Process for Preparing an Activin Receptor-like Kinase Inhibitor
15 Dec 22
Brian Heinrich, Gordon Wilkie, Dominik Siegel, Harald Ohmer
Filed: 2 Oct 20
Utility
Treatment of Mast Cell Diseases and Eosinophilic Disorders
24 Nov 22
Brenton Mar, Alexandra Grassian
Filed: 3 Nov 20
Utility
MAP4K1 Inhibitors
13 Oct 22
One embodiment of the disclosure is a compound represented by Formula I or a pharmaceutically acceptable salt thereof.
Jason D. Brubaker, Chandrasekhar V. Miduturu, Michael J. Burke, Thomas A. Dineen, Joseph L. Kim, Joshua T. Close, Emanuele Perola
Filed: 14 Jan 21
Utility
Inhibitors of Ret
6 Oct 22
Described herein are compounds that inhibit wild-type RET and its resistant mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.
Jason D. Brubaker, Joseph L. Kim, Kevin J. Wilson, Douglas Wilson, Lucian V. DiPietro
Filed: 11 Feb 22